Trial Profile
A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2020
Price :
$35
*
At a glance
- Drugs PF 6273340 (Primary) ; Ibuprofen; Pregabalin
- Indications Pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 27 Nov 2017 Primary endpoint (Electrical pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
- 27 Nov 2017 Primary endpoint (Pressure pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
- 27 Nov 2017 Primary endpoint (Ultra-violet light sensitized pain detection threshold (50mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology